Effects of candesartan cilexetil in patients with systemic hypertension

The objectives of this double-blind, multicenter, randomized, parallel-arm, placebo-controlled study were to evaluate the dose-related efficacy, tolerability, and safety of candesartan cilexetil, a potent, AT 1 selective, long-acting angiotensin II receptor blocker, in 365 adult patients with system...

Full description

Saved in:
Bibliographic Details
Published in:The American journal of cardiology 1998-10, Vol.82 (8), p.961-965
Main Authors: Reif, Max, White, William B., Fagan, Timothy C., Oparil, Suzanne, Flanagan, Terry L., Edwards, Dianne T., Cushing, Daniel J., Michelson, Eric L.
Format: Article
Language:English
Subjects:
Antihypertensive agents
Biological and medical sciences
Blood pressure
Cardiovascular system
Clinical trials
Hypertension
Medical sciences
Pharmacology. Drug treatments
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The objectives of this double-blind, multicenter, randomized, parallel-arm, placebo-controlled study were to evaluate the dose-related efficacy, tolerability, and safety of candesartan cilexetil, a potent, AT 1 selective, long-acting angiotensin II receptor blocker, in 365 adult patients with systemic hypertension and mean sitting diastolic blood pressure (BP) of 95 to 114 mm Hg. Patients received either placebo or candesartan cilexetil 2, 4, 8, 16, or 32 mg once daily for 8 weeks. All doses of candesartan cilexetil reduced trough (24 hours after treatment) sitting diastolic and systolic BP significantly compared with placebo (p
ISSN:0002-9149
1879-1913
DOI:10.1016/S0002-9149(98)00627-4